



Peginterferon/Ribavirin-Experienced, Genotype 1a Patients With Compensated Cirrhosis

Recommended and alternative regimens listed by evidence level and alphabetically for:

Peginterferon/Ribavirin-Experienced, Genotype 1a Patients With Compensated Cirrhosis^a

RECOMMENDED	DURATION	RATING 
Daily fixed-dose combination of elbasvir (50 mg)/grazoprevir (100 mg) for patients without baseline NS5A RASs ^b for elbasvir	12 weeks	I, A
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)	12 weeks	I, A
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg) ^c	12 weeks	I, B
ALTERNATIVE	DURATION	RATING 
Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) plus weight-based ribavirin	12 weeks	I, A

^a For [decompensated cirrhosis](#), please refer to the appropriate section.

^b Includes genotype 1a RASs at amino acid positions 28, 30, 31, or 93 known to confer [antiviral resistance to elbasvir](#). Baseline testing for these RASs is recommended for patients receiving elbasvir/grazoprevir-based regimens.

^c Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information.

Last update: November 6, 2019